Therapy Directory

Lenvatinib clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Lenvatinib as a study intervention. Browse Lenvatinib recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 8:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

156

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Tumors
Interventions: Lenvatinib, Pembrolizumab; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 50
States / cities: Anchorage, Alaska • Oro Valley, Arizona • Tucson, Arizona + 34 more

Conditions: Tumors, Solid Malignant Tumors, Osteosarcoma, Differentiated Thyroid Cancer (DTC)
Interventions: Lenvatinib, Ifosfamide, Etoposide; Drug
Lead sponsor: Eisai Limited; Industry
Eligibility: 2 Years to 25 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Ovarian Cancer
Interventions: Lenvatinib, Carboplatin, Gemcitabine; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Endometrial Cancer
Interventions: Lenvatinib; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 36
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 33 more

Conditions: Refractory Solid Tumors, Lymphomas
Interventions: Lenvatinib, Moxifloxacin 400 mg, Placebos (matched to 4 mg and 10 mg lenvatinib capsules).; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2010
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Thyroid Cancer
Interventions: Lenvatinib, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 392 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 38
States / cities: Little Rock, Arkansas • La Jolla, California • Los Gatos, California + 30 more

Conditions: Non Clear Cell Renal Cell Carcinoma (nccRCC)
Interventions: lenvatinib, everolimus; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 8
States / cities: Tampa, Florida • Chicago, Illinois • Boston, Massachusetts + 5 more

Conditions: Differentiated Thyroid Gland Carcinoma, Thyroid Gland Follicular Carcinoma, Thyroid Gland Papillary Carcinoma
Interventions: Lenvatinib; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Glioma
Interventions: Lenvatinib, Bevacizumab; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 3
States / cities: Tampa, Florida • Boston, Massachusetts • Durham, North Carolina

Conditions: Fallopian Tube Carcinoma, Recurrent Ovarian Cancer, Primary Peritoneal Carcinoma, Recurrent Endometrial Cancer
Interventions: Lenvatinib Mesylate, Paclitaxel, Pharmacological Study; Drug · Other
Lead sponsor: Floor Backes; Other
Eligibility: 18 Years and older · Female only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Rectal Cancer, Rectal Adenocarcinoma
Interventions: Lenvatinib, Capecitabine, External Radiation Therapy (XRT); Drug · Radiation
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Hepatocellular Carcinoma (HCC)
Interventions: Lenvatinib, Sorafenib; Drug
Lead sponsor: Eisai Limited; Industry
Eligibility: 18 Years and older
Enrollment: 954 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 21
States / cities: Los Angeles, California • Sacramento, California • San Francisco, California + 18 more

About this Lenvatinib clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Lenvatinib as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Lenvatinib.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Lenvatinib clinical trials

Filter and sort this therapy

Live official records

A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors

Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma

E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125

Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression

A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)

A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease

Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer

A Study in Subjects With Recurrent Malignant Glioma

Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer

Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma

A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma

About this Lenvatinib clinical trials directory page